Download PDF
Nephrologie aktuell 2025; 29(04): 164-169
DOI: 10.1055/a-2529-8299
Schwerpunkt
Nephrologie

Lebensqualität bei Dialysepatienten unter Anämietherapie

KDIGO 2025 – Hämoglobinkontrolle vs. Risiko kardiovaskulärer Nebenwirkungen
Vincent Brandenburg
Klinik für Kardiologie und Nephrologie, Rhein-Maas Klinikum GmbH, Würselen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die Lebensqualität (QoL: „Quality of Life“) von Patienten zu beachten und ihre mögliche Verbesserung anzustreben, gehört zu den zentralen ärztlichen Alltagsaufgaben. Bei Dialysepatienten als chronisch Kranken gilt umso mehr, Einschränkungen der QoL systematisch zu erfassen. Die renale Anämie ist ein relevanter Prädiktor eingeschränkter QoL. Mindestens so alt wie die Zulassung von Erythropoese stimulierenden Agenzien (ESAs) ist die Forschung, wie eine spezifische Therapie der renalen Anämie (gleichzeitig) neben dem Hämoglobinwert und harten klinischen Endpunkten auch Aspekte der QoL verbessern helfen kann. Hierbei spielen Substanzwahl und auch der angestrebte Hämoglobin- bzw. Hämatokritwert eine Rolle. Es versteht sich von selbst, dass bei einem subjektiv beurteilten Therapieziel, die individuellen (und vielleicht auch im Verlauf wechselnden) Wünsche der Patienten in die Therapieplanung einbezogen werden sollten.



Publication History

Article published online:
21 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Yapa HE, Purtell L, Chambers S. et al. The Relationship Between Chronic Kidney Disease, Symptoms and Health-Related Quality of Life: A Systematic Review. J Ren Care 2020; 46: 74-84
    CrossrefPubMedSearch in Google Scholar
  • 2 Fletcher BR, Damery S, Aiyegbusi OL. et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Med 2022; 19: e1003954
    CrossrefPubMedSearch in Google Scholar
  • 3 Verberne WR, van den Wittenboer ID, Voorend CGN. et al. Health-related quality of life and symptoms of conservative care versus dialysis in patients with end-stage kidney disease: a systematic review. Nephrol Dial Transplant 2021; 36: 1418-1433
    CrossrefPubMedSearch in Google Scholar
  • 4 Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105: S117-S314
    CrossrefPubMedSearch in Google Scholar
  • 5 Morton RL, Tong A, Howard K. et al. The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. BMJ 2010; 340: c112
    CrossrefPubMedSearch in Google Scholar
  • 6 Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835-840
    CrossrefPubMedSearch in Google Scholar
  • 7 Hays RD, Kallich JD, Mapes DL. et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 3: 329-338
    CrossrefPubMedSearch in Google Scholar
  • 8 Weisbord SD, Fried LF, Arnold RM. et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 2004; 27: 226-240
    CrossrefPubMedSearch in Google Scholar
  • 9 Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
    CrossrefPubMedSearch in Google Scholar
  • 10 Loosman WL, Hoekstra T, van Dijk S. et al. Short-Form 12 or Short-Form 36 to measure quality-of-life changes in dialysis patients?. Nephrol Dial Transplant 2015; 30: 1170-1176
    CrossrefPubMedSearch in Google Scholar
  • 11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD). Im Internet: Accessed February 17, 2025 at: https://kdigo.org/wp-content/uploads/2024/11/KDIGO-2025-Anemia-in-CKD-Guideline_Public-Review-Draft_Nov42024.pdf
  • 12 Khan A, Ghulam Hussain S, Mushtaq S. et al. Prevalence and management of anemia and impact of treatment burden on health-related quality of life in chronic kidney disease and dialysis patients. J Pharm Policy Pract 2024; 17: 2427779
    CrossrefPubMedSearch in Google Scholar
  • 13 Phillips T, Harris S, Aiyegbusi OL. et al. Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort. Clin Kidney J 2024; 17: sfae010
    CrossrefPubMedSearch in Google Scholar
  • 14 Shen Y, Wang J, Yuan J. et al. Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Anemia among Chinese patients with chronic kidney disease and its association with quality of life – results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2021; 22: 64
    CrossrefPubMedSearch in Google Scholar
  • 15 Van Haalen H, Jackson J, Spinowitz B. et al. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 2020; 21: 88
    CrossrefPubMedSearch in Google Scholar
  • 16 Reilly Associates. WPAI General Information. Stand: 2019 Im Internet: Accessed February 17, 2025 at: http://www.reillyassociates.net/WPAI_General.html
    Search in Google Scholar
  • 17 Bhandari S, Parfrey P, White C. et al. Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. J Nephrol 2023; 36: 1651-1662
    CrossrefPubMedSearch in Google Scholar
  • 18 Diskin J, Diskin CJ. Mental Effects of Excess Parathyroid Hormone in Hemodialysis Patients: A Possible Role for Parathyroid 2 Hormone Receptor?. Ther Apher Dial 2020; 24: 285-289
    CrossrefPubMedSearch in Google Scholar
  • 19 Farag YM, Keithi-Reddy SR, Mittal BV. et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol 2011; 75: 524-533
    CrossrefPubMedSearch in Google Scholar
  • 20 Fraser SDS, Phillips T. Quality of life in people with chronic kidney disease: focusing on modifiable risk factors. Curr Opin Nephrol Hypertens 2024; 33: 573-582
    CrossrefPubMedSearch in Google Scholar
  • 21 Akizawa T, Pisoni RL, Akiba T. et al. Japanese haemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS. Nephrol Dial Transplant 2008; 23: 3643-3653
    CrossrefPubMedSearch in Google Scholar
  • 22 Locatelli F, Del Vecchio L. Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD. Kidney Int 2023; 103: 1025-1027
    CrossrefPubMedSearch in Google Scholar
  • 23 Hull KL, Reast J, Clair C. et al. UK survey of patient and caregiver perspectives on the impact of chronic kidney disease-associated anaemia. BMJ Open 2024; 14: e087802
    CrossrefPubMedSearch in Google Scholar
  • 24 Jiang JL, Ren W, Song J. et al. The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients. Braz J Med Biol Res 2013; 46: 629-633
    CrossrefPubMedSearch in Google Scholar
  • 25 Shepshelovich D, Rozen-Zvi B, Avni T. et al. A. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68: 677-690
    CrossrefPubMedSearch in Google Scholar
  • 26 Freburger JK, Ellis AR, Wang L. et al. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. Am J Kidney Dis 2016; 67: 271-282
    CrossrefPubMedSearch in Google Scholar
  • 27 Agarwal R, Rizkala AR, Bastani B. et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454
    CrossrefPubMedSearch in Google Scholar
  • 28 Macdougall IC, White C, Anker SD. et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2019; 380: 447-458
    CrossrefPubMedSearch in Google Scholar
  • 29 Sackeyfio A, Lopes RD, Kovesdy CP. et al. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clin Kidney J 2023; 17: sfad298
    CrossrefPubMedSearch in Google Scholar
  • 30 Chung EY, Palmer SC, Saglimbene VM. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2023; 2: CD010590
    CrossrefPubMedSearch in Google Scholar
  • 31 Singh AK, Szczech L, Tang KL. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
    CrossrefPubMedSearch in Google Scholar
  • 32 Pfeffer MA, Burdmann EA, Chen CY. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-1032
    CrossrefPubMedSearch in Google Scholar
  • 33 Drüeke TB, Locatelli F, Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
    CrossrefPubMedSearch in Google Scholar
  • 34 [Anonym] Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578
    CrossrefPubMedSearch in Google Scholar
  • 35 Beusterien KM, Nissenson AR, Port FK. et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
    CrossrefPubMedSearch in Google Scholar
  • 36 Foley RN, Parfrey PS, Morgan J. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
    CrossrefPubMedSearch in Google Scholar
  • 37 Besarab A, Bolton WK, Browne JK. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
    CrossrefPubMedSearch in Google Scholar
  • 38 Moreno F, Sanz-Guajardo D, López-Gómez JM. et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-342
    CrossrefPubMedSearch in Google Scholar
  • 39 Spinowitz B, Pecoits-Filho R, Winkelmayer WC. et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ 2019; 22: 593-604
    CrossrefPubMedSearch in Google Scholar
  • 40 Collister D, Komenda P, Hiebert B. et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472-478
    CrossrefPubMedSearch in Google Scholar